A Phase 2 interventional study of VigantOL oil plus interferon beta-1a (Rebif) and Placebo plus interferon beta-1a (Rebif) in Relapsing-Remitting Multiple Sclerosis, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 38 sites in 12 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-11-28.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.
Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 7th largest by enrollment, is the only one that started in 2011, is one of 3 in phase 2, and was the 16th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 260 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 80 across the 21 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 8 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany: none open now, none under way, none of them phase 3. Of 39 finished, 20 (51%) have results posted.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, this one is the 9th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2011, is one of 6 in phase 2, and was the 29th registered.
Merck KGaA, Darmstadt, Germany’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 40 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone supplement (cholecalciferol). Low levels of Vitamin D have been described to be associated with a higher risk of developing Multiple Sclerosis (MS), and it is known that up to 90% of patients with Multiple Sclerosis have Vitamin D deficiency.
Rebif® is known to be an effective treatment for slowing down the progression of MS. The purpose of this research trial is to evaluate if VigantOL® oil on top of Rebif® has any benefit on the progression of MS compared to Rebif® and placebo.
Disease activity will be assessed by clinical examination and Magnetic Resonance Imaging (MRI). The planned study treatment duration for each study participant is 48 weeks, and the study consists of a total of 8 visits. Study participants who are already passed Week 48 at the time of approval of Protocol Amendment 5 will have a study duration of 96 weeks and a total of 12 visits.
During the study, the participant will undergo physical examination, neurological assessments, safety assessments, blood tests and urinalysis (including pregnancy tests).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VigantOL oil plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
Drug: VigantOL oil plus interferon beta-1a (Rebif)
Placebo daily plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
Drug: Placebo plus interferon beta-1a (Rebif)
Rebif alone in subjects with 25-hydroxy-vitamin D plasma levels equal or higher than 150 nmol/L
Biological: Interferon beta-1a (Rebif®) alone
Drug page: Interferon beta-1a
VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day \[mcg/day\]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
Rebif® 44 mcg tiw, sub-cutaneously alone.
Percentage of Subjects With Disease Activity Free Status up to Week 48
Disease activity free status was defined as absence of any of the clinical and imaging parameters related to the assessment of disease activity; no relapses, no expanded disability status scale (EDSS) progression and no new gadolinium (Gd)-enhancing or relaxation time 2 (T2) magnetic resonance imaging (MRI) lesions.
Time frame: Up to Week 48
Percentage of Relapse-free Subjects at Week 48
A relapse was defined as the development of new or the exacerbation of existing neurological symptoms or signs, in the absence of fever, lasting for 24 hours and with a previous period for more than 30 days with a stable or an improving condition.
Time frame: Week 48
Percentage of Subjects Free From Any Expanded Disability Status Scale (EDSS) Progression at Week 48
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. An EDSS progression was defined as an increase of the EDSS score of at least 1.0 point compared to baseline (SD1) for subjects with a baseline EDSS ≤ 4.0. For subjects with an EDSS score of 0 at baseline (SD1), EDSS progression was defined as an increase of at least 1.5 points. A confirmed EDSS progression was defined as an EDSS progression confirmed after 24 weeks.
Time frame: Week 48
Number od Subjects With Confirmed EDSS Progression
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. An EDSS progression was defined as an increase of the EDSS score of at least 1.0 point compared to baseline (SD1) for subjects with a baseline EDSS ≤ 4.0. For subjects with an EDSS score of 0 at baseline (SD1), EDSS progression was defined as an increase of at least 1.5 points. A confirmed EDSS progression was defined as an EDSS progression confirmed after 24 weeks.
Time frame: Baseline upto 48 Weeks
Cumulative Number of Relaxation Time 1 (T1) Gadolinium Enhancing Lesions at Week 48
Time frame: 48 Weeks
Mean Number of Combined Unique Active (CUA) Lesions Per Subject Per Scan at Week 48
CUA lesions was defined as new T1 (Gd enhancing) lesions, new Relaxation time 2 (T2) lesions, or enlarging T2 lesions.
Time frame: 48 Weeks
Cumulative Number of New Combined Unique Active (CUA) Lesions at Week 48
CUA lesions was defined as new T1 (Gd enhancing) lesions, new T2 lesions, or enlarging T2 lesions.
Time frame: 48 Weeks
Mean Change From Baseline in the Total Volume of T2 Lesions at Week 48 (T2 Burden of Disease)
Time frame: Baseline, 48 Weeks
Percentage of Subjects Free From T1 Gadolinium Enhancing Lesions at Week 48
Time frame: 48 Weeks
Percentage of Subjects Free From New T1 Hypointense Lesions (Black Holes) at Week 48
Time frame: 48 Weeks
Percentage of New T1 Hypointense Lesions (Black Holes) at Week 48 Within the Subgroup of New or Enlarging Non-enhancing T2 Lesions
Time frame: 48 Weeks
Number of Subjects With Relapse
Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.
Time frame: Baseline upto 48 weeks
Annualized Relapse Rate at Week 48
Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.
Time frame: 48 weeks
Total Number of Reported Relapses at All Time Points up to 48 Weeks
Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.
Time frame: 48 weeks
Percentage of Subjects Treated With Glucocorticoids Due to Relapses
Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.
Time frame: Baseline upto 48 weeks
Mean Change From Baseline in the Total Volume of T1 Hypo Intense Lesions at Week 48
Time frame: Baseline, 48 Weeks
| Milestone | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Started | 115 | 117 |
| Treated | 113 | 116 |
| Completed | 98 | 88 |
| Not completed | 17 | 29 |
| Withdrew: Prematurely withdrawn from the study | 17 | 29 |
Disease activity free status was defined as absence of any of the clinical and imaging parameters related to the assessment of disease activity; no relapses, no expanded disability status scale (EDSS) progression and no new gadolinium (Gd)-enhancing or relaxation time 2 (T2) magnetic resonance imaging (MRI) lesions.
| percentage of subjects | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Percentage of Subjects With Disease Activity Free Status up to Week 48 | 37.2 | 35.3 |
A relapse was defined as the development of new or the exacerbation of existing neurological symptoms or signs, in the absence of fever, lasting for 24 hours and with a previous period for more than 30 days with a stable or an improving condition.
| percentage of subjects | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Percentage of Relapse-free Subjects at Week 48 | 78.8 | 75.0 |
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. An EDSS progression was defined as an increase of the EDSS score of at least 1.0 point compared to baseline (SD1) for subjects with a baseline EDSS ≤ 4.0. For subjects with an EDSS score of 0 at baseline (SD1), EDSS progression was defined as an increase of at least 1.5 points. A confirmed EDSS progression was defined as an EDSS progression confirmed after 24 weeks.
| percentage of subjects | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Percentage of Subjects Free From Any Expanded Disability Status Scale (EDSS) Progression at Week 48 | 71.7 | 75.0 |
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. An EDSS progression was defined as an increase of the EDSS score of at least 1.0 point compared to baseline (SD1) for subjects with a baseline EDSS ≤ 4.0. For subjects with an EDSS score of 0 at baseline (SD1), EDSS progression was defined as an increase of at least 1.5 points. A confirmed EDSS progression was defined as an EDSS progression confirmed after 24 weeks.
| subjects | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Number od Subjects With Confirmed EDSS Progression | 8 | 4 |
| lesions per subject per scan | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Cumulative Number of Relaxation Time 1 (T1) Gadolinium Enhancing Lesions at Week 48 | 0.36 ± 1.73 | 0.25 ± 0.67 |
CUA lesions was defined as new T1 (Gd enhancing) lesions, new Relaxation time 2 (T2) lesions, or enlarging T2 lesions.
| lesions per subject per scan | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Mean Number of Combined Unique Active (CUA) Lesions Per Subject Per Scan at Week 48 | 1.09 ± 3.84 | 1.49 ± 4.31 |
CUA lesions was defined as new T1 (Gd enhancing) lesions, new T2 lesions, or enlarging T2 lesions.
| lesions per subject per scan | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Cumulative Number of New Combined Unique Active (CUA) Lesions at Week 48 | 1.09 ± 3.84 | 1.49 ± 4.31 |
| millimeter^3 (mm^3) | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Mean Change From Baseline in the Total Volume of T2 Lesions at Week 48 (T2 Burden of Disease) | 130.38 ± 830.82 | 95.75 ± 401.87 |
| percentage of subjects | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Percentage of Subjects Free From T1 Gadolinium Enhancing Lesions at Week 48 | 83.2 | 70.7 |
| percentage of subjects | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Percentage of Subjects Free From New T1 Hypointense Lesions (Black Holes) at Week 48 | 78.8 | 63.8 |
| percentage of new T1 hypointense lesions | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Percentage of New T1 Hypointense Lesions (Black Holes) at Week 48 Within the Subgroup of New or Enlarging Non-enhancing T2 Lesions | 20.11 ± 34.72 | 27.70 ± 39.33 |
Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.
| subjects | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Number of Subjects With Relapse | 24 | 29 |
Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.
| relapse per year | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Annualized Relapse Rate at Week 48 | 0.28 ± 0.59 | 0.41 ± 0.83 |
Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.
| number of relapse per subject | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Total Number of Reported Relapses at All Time Points up to 48 Weeks | 0.25 ± 0.53 | 0.34 ± 0.63 |
Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.
| percentage of subjects | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Percentage of Subjects Treated With Glucocorticoids Due to Relapses | 15.9 | 20.7 |
| millimeter^3 (mm^3) | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Mean Change From Baseline in the Total Volume of T1 Hypo Intense Lesions at Week 48 | 20.88 ± 140.56 | 18.47 ± 68.08 |
Disease activity free (DAF) status was defined as absence of any of the clinical and imaging parameters related to the assessment of disease activity; no relapses, no confirmed expanded disability status scale (EDSS) progression and no new gadolinium (Gd)-enhancing or relaxation time 2 (T2) magnetic resonance imaging (MRI) lesions. Confirmed EDSS progression was defined as an EDSS progression confirmed after 24 weeks.
| percentage of subjects | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| Percentage of Subjects With Disease Activity Free Status (Alternate Definition) at Week 48 | 47.8 | 37.9 |
Collected over Baseline up to end of trial (EOT: 50 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VigantOL Oil Interferon Beta-1a (Rebif) | — | 18/113 (15.9%) | 99/113 (87.6%) |
| Placebo Interferon Beta-1a (Rebif) | — | 8/116 (6.9%) | 93/116 (80.2%) |
| Event | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 8/113 | 6/116 |
| Abscess limbInfections and infestations | 1/113 | 0/116 |
| AppendicitisInfections and infestations | 1/113 | 0/116 |
| CellulitisInfections and infestations | 1/113 | 0/116 |
| PneumoniaInfections and infestations | 1/113 | 0/116 |
| PyelonephritisInfections and infestations | 1/113 | 0/116 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/113 | 0/116 |
| Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/113 | 0/116 |
| DepressionPsychiatric disorders | 1/113 | 0/116 |
| SyncopeNervous system disorders | 1/113 | 0/116 |
| Event | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) |
|---|---|---|
| HeadacheNervous system disorders | 20/113 | 21/116 |
| InfluenzaInfections and infestations | 13/113 | 19/116 |
| NasopharyngitisInfections and infestations | 18/113 | 17/116 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 13/113 | 6/116 |
| FatigueGeneral disorders | 8/113 | 13/116 |
| Influenza like illnessGeneral disorders | 12/113 | 13/116 |
| Urinary tract infectionInfections and infestations | 12/113 | 6/116 |
| PyrexiaGeneral disorders | 7/113 | 12/116 |
| DiarrhoeaGastrointestinal disorders | 10/113 | 7/116 |
| Back painMusculoskeletal and connective tissue disorders | 10/113 | 7/116 |
Baseline analysis set included all randomized subjects.
| Age, Continuous(years) | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) | Total |
|---|---|---|---|
| Mean | 34.2 ± 8.1 | 33.6 ± 9.3 | 33.9 ± 8.8 |
| Sex: Female, Male(Participants) | VigantOL Oil Interferon Beta-1a (Rebif) | Placebo Interferon Beta-1a (Rebif) | Total |
|---|---|---|---|
| Female | 78 | 79 | 157 |
| Male | 37 | 38 | 75 |
The record gives a start of Feb 2011, a primary completion of Apr 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Multiple Sclerosis, Relapsing-Remitting →
Merck KGaA, Darmstadt, Germany →